Table 4.
Outcomes and the medications administered in AAV patients during follow-up
| AAV patients | Values |
|---|---|
| Clinical outcomes during follow-up (N, (%)) | |
| All-cause mortality (N, (%)) | 18 (10.8) |
| Follow-up duration based on all-cause mortality (months) | 33.7 (65.6) |
| CVA (N, (%)) | 16 (9.6) |
| Follow-up duration based on CVA (months) | 30.5 (64.0) |
| CVD (N, (%)) | 14 (8.4) |
| Follow-up duration based on CVD (months) | 32.8 (63.6) |
| Medications administered during follow-up (N, (%)) | |
| Glucocorticoid | 155 (92.8) |
| Cyclophosphamide | 87 (52.1) |
| Rituximab | 29 (17.4) |
| Azathioprine | 82 (49.1) |
| Mycophenolate mofetil | 22 (13.2) |
| Tacrolimus | 11 (6.6) |
| Methotrexate | 12 (7.2) |
Values are expressed as a median (interquartile range, IQR) or N (%)
AAV ANCA-associated vasculitis, ANCA Antineutrophil cytoplasmic antibody, CVA Cerebrovascular accident, CVD Cardiovascular disease